Given that four protein biomarkers mentioned above were consistently altered in AD or aMCI plasma in the discovery and validation cohort, we examined whether they could also be used to classify AD patients from controls, and aMCI patients from controls by calculating the ROCs of KLK4, GSN, sLRP1 and Caspase 3 and their combination. This evidence concerns the gene GSN and Alzheimer disease.